Analysts are on the Bearish side about Circassia Pharmaceuticals Plc (LON:CIR) this week.

January 13, 2018 - By Louis Casey

 Analysts are on the Bearish side about Circassia Pharmaceuticals Plc (LON:CIR) this week.
Investors sentiment decreased to 1 in Q3 2017. Its down 0.18, from 1.18 in 2017Q2. It dived, as 16 investors sold Circassia Pharmaceuticals Plc shares while 33 reduced holdings. 14 funds opened positions while 35 raised stakes. 16.23 million shares or 2.40% less from 16.63 million shares in 2017Q2 were reported.
Elk Creek Prtnrs Ltd Liability accumulated 280,111 shares. Fmr Ltd Liability Company, a Massachusetts-based fund reported 70,007 shares. Bankshares Of Montreal Can holds 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR) for 1,145 shares. Century accumulated 42,357 shares or 0% of the stock. Invesco reported 28,104 shares stake. Wilen Invest Mngmt Corporation owns 10,242 shares. Texas Permanent School Fund, a Texas-based fund reported 12,046 shares. State Of Tennessee Treasury Department reported 0% stake. Silvercrest Asset Mngmt Grp Inc Ltd Limited Liability Company reported 646,383 shares. Pacific Alternative Asset Mgmt Company Ltd has 0.12% invested in Circassia Pharmaceuticals Plc (LON:CIR) for 20,901 shares. Wells Fargo And Mn holds 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR) for 20,635 shares. 2,589 were reported by Tower Ltd Liability Com (Trc). Gamco Invsts Et Al accumulated 0.5% or 1.49 million shares. Deutsche State Bank Ag owns 15,995 shares or 0% of their US portfolio. Campbell And Adviser Lc reported 4,008 shares.

Circassia Pharmaceuticals Plc (LON:CIR) Ratings Coverage

Among 6 analysts covering Circassia Pharmaceuticals (LON:CIR), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Circassia Pharmaceuticals had 49 analyst reports since October 27, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Monday, March 14 by JP Morgan. The stock of Circassia Pharmaceuticals Plc (LON:CIR) has “Buy” rating given on Tuesday, April 4 by Stifel Nicolaus. Cantor Fitzgerald maintained Circassia Pharmaceuticals Plc (LON:CIR) on Tuesday, September 27 with “Hold” rating. The firm has “Hold” rating given on Tuesday, October 31 by Peel Hunt. The stock of Circassia Pharmaceuticals Plc (LON:CIR) has “Hold” rating given on Friday, March 17 by Cantor Fitzgerald. Cantor Fitzgerald maintained it with “Buy” rating and GBX 500 target in Friday, March 11 report. The stock of Circassia Pharmaceuticals Plc (LON:CIR) has “Buy” rating given on Tuesday, April 25 by Numis Securities. The rating was maintained by Peel Hunt with “Hold” on Wednesday, September 27. As per Thursday, January 4, the company rating was maintained by Peel Hunt. The stock of Circassia Pharmaceuticals Plc (LON:CIR) has “Buy” rating given on Wednesday, September 27 by Numis Securities. Below is a list of Circassia Pharmaceuticals Plc (LON:CIR) latest ratings and price target changes.

04/01/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
04/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 180.00 New Target: GBX 180.00 Maintain
31/10/2017 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
28/09/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 120.00 New Target: GBX 110.00 Maintain
27/09/2017 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
27/09/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 180.00 New Target: GBX 180.00 Maintain
08/09/2017 Broker: JP Morgan Rating: Neutral Maintain
07/09/2017 Broker: Numis Securities Rating: Buy New Target: GBX 180.00 Maintain

The stock decreased 0.42% or GBX 0.4 during the last trading session, reaching GBX 94.6. About 69,504 shares traded. Circassia Pharmaceuticals Plc (LON:CIR) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease . The company has market cap of 315.46 million GBP. It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. It currently has negative earnings. The companyÂ’s asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide.

More news for Circassia Pharmaceuticals Plc (LON:CIR) were recently published by: Ft.com, which released: “Circassia shares drop after cat allergy drug fails in trial” on June 20, 2016. Ft.com‘s article titled: “Circassia halts allergy programme after failed trials” and published on April 18, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.